Amy K. LeBlanc | |
---|---|
Alma mater | Michigan State University (BS, DVM) |
Scientific career | |
Fields | Veterinary oncology, cancer biology, comparative medicine |
Institutions | University of Tennessee National Cancer Institute |
Amy K. LeBlanc is an American veterinary oncologist and biologist researching animal modeling for development of new cancer drugs and imaging agents, and identification of imaging biomarkers, development and optimization of PET imaging hardware and imaging protocols. She is a senior scientist in the molecular imaging program and director of the Comparative Oncology Program at the National Cancer Institute. LeBlanc was previously an associate professor at the University of Tennessee College of Medicine and College of Veterinary Medicine.
LeBlanc graduated from Michigan State University with a B.S. and D.V.M. She completed a rotating internship in small animal medicine and surgery at Texas A&M University and a residency in companion animal oncology at Louisiana State University. She is board-certified by the American College of Veterinary Internal Medicine. [1]
LeBlanc was an associate professor with tenure and director of translational research at the University of Tennessee College of Veterinary Medicine (CVM) and University of Tennessee College of Medicine. LeBlanc's group at the University of Tennessee published the first comprehensive studies describing molecular imaging of dogs and cats using PET-CT, focusing on the forward and back-translation of 18F-labelled radiopharmaceuticals. [1]
LeBlanc is a board-certified veterinary oncologist and senior scientist in the molecular imaging program at the National Cancer Institute (NCI). She is director of the NCI's Comparative Oncology Program. Her research focus is in animal modeling for development of new cancer drugs and imaging agents, and identification of imaging biomarkers, development and optimization of PET imaging hardware and imaging protocols. In her position, she oversees and manages the operations of the Comparative Oncology Trials Consortium (COTC), which designs and executes clinical trials of new cancer therapies in tumor-bearing pet dogs. [1] [2]
The Wistar Institute is an independent, nonprofit research institution in biomedical science with special focuses in oncology, immunology, infectious disease and vaccine research. Located on Spruce Street in Philadelphia’s University City neighborhood, Wistar was founded in 1892 as a nonprofit institution to focus on biomedical research and training.
North Carolina State University College of Veterinary Medicine is an American educational institution located in Raleigh, North Carolina that offers master's and doctorate-level degree programs; interdisciplinary research in a range of veterinary and comparative medicine topics through centers, institutes, programs and laboratories; and external engagement through public service programs and activities.
The University of Florida College of Veterinary Medicine is the veterinary school of the University of Florida in Gainesville, Florida. The college only enrolls professional program D.V.M. students and graduate students pursuing M.S. or Ph.D. degrees. No undergraduates are enrolled in the college.
Elizabeth M. Jaffee is an American oncologist specializing in pancreatic cancer and immunotherapy.
Jason S. Lewis is a British radiochemist whose work relates to oncologic therapy and diagnosis. His research focus is a molecular imaging-based program focused on radiopharmaceutical development as well as the study of multimodality small- and biomolecule-based agents and their clinical translation. He has worked on the development of small molecules as well as radiolabeled peptides and antibodies probing the overexpression of receptors and antigens on tumors.
David Argyle BVMS DECVIM-CA (Oncology) FRSE FRSA FRCVS is Head of the College of Medicine and Veterinary Medicine at the University of Edinburgh.
Christine Campo Alewine is an American oncologist and biologist researching immunotoxin therapeutics in pancreatic cancer. She is an investigator at the National Cancer Institute.
Christina Messineo Annunziata is an American medical oncologist researching molecular signal transduction in ovarian cancer. She is an investigator in the National Cancer Institute's women's malignancies branch and head of the translational genomics section.
Andrea B. Apolo is an American medical oncologist specialized in bladder cancer research. She is an investigator in the National Cancer Institute's genitourinary malignancies branch and head of the bladder cancer section.
Rosandra N. Kaplan is an American pediatric oncologist and scientist specialized in translational and clinical research on the mechanisms of cancer spread and the role of the tumor microenvironment in cancer progression. She is a principal investigator and head of the tumor microenvironment and metastasis branch at the National Cancer Institute.
Jung-Min Lee is a South Korean-American medical oncologist and physician-scientist focused on the early clinical drug development and translational studies of targeted agents in BRCA mutation-associated breast or ovarian cancer, high-grade epithelial ovarian cancer, and triple-negative breast cancer. She is a NIH Lasker Clinical Research Scholar and principal investigator in the Women's Malignancies Branch at the National Cancer Institute.
Nirali N. Shah is an American physician-scientist and pediatric hematologist-oncologist, serving as head of the hematologic malignancies section of the pediatric oncology branch at the National Cancer Institute. She researches the translation of immunotherapeutic approaches to treat high-risk hematologic malignancies in children, adolescents and young adults.
Worta J. McCaskill-Stevens was an American physician-scientist and medical oncologist specialized in cancer disparities research, management of comorbidities within clinical trials, and molecular research for cancer prevention interventions. She was chief of the community oncology and prevention trials research group at the National Cancer Institute.
Bríd M. Ryan is an Irish biomedical scientist and cancer researcher. She was an investigator at the National Cancer Institute from 2013 to 2021.
Nilofer Saba Azad is an American oncologist and physician-scientist specialized in gastrointestinal, colorectal, cholangiocarcinoma, and pancreaticobiliary cancers. She is a professor at the Johns Hopkins School of Medicine and oversees clinical trials at the Sidney Kimmel Comprehensive Cancer Center.
Sharon A. Savage is an American pediatric hematologist/oncologist. She is the clinical director of the National Cancer Institute's Division of Cancer Epidemiology and Genetics.
Brigitte C. Widemann is German-American pediatric oncologist. She is chief of the pediatric oncology branch and clinical deputy director of the center for cancer research at the National Cancer Institute. She is also the special advisor to the NCI director for childhood cancer.
Christine Dorothy Berg is an American radiation oncologist and physician-scientist who was chief of the early detection research group at the National Cancer Institute.
Maria Teresa Landi is an Italian epidemiologist and oncologist who researches genetic and environmental determinants of lung cancer and melanoma. At the National Cancer Institute, she is a senior investigator in the integrative tumor epidemiology branch and a senior advisor for genomic epidemiology. Landi is an associate professor of epidemiology at the Johns Hopkins Bloomberg School of Public Health.
Kathy J. Helzlsouer is an American oncologist, internist, and cancer epidemiologist who investigates cancer etiology and prevention, women's health, genetic counseling, and translational research. At the National Cancer Institute, she is the associate director of the epidemiology and genomics research program and chief medical officer for the division of cancer control and population sciences.